Ascentage Pharma Takes Strides in Global Hematology Oncology Expansion
Leading global hematology oncology company, Ascentage Pharma, has made significant strides in advancing its strategic objectives during the first half of 2026. The company's recent conference call provided insights into its progress, which we'll delve into below.
As reported on the company's unaudited financial results for the six months ending June 30, 2026, Ascentage Pharma saw a notable increase in total revenue, growing to $44.5 million - an impressive 29% year-over-year growth rate. This surge can be attributed to product sales of $41.6 million on a constant exchange rate basis.
A key highlight from the conference call was Dr. Dajun Yang's statement that Ascentage Pharma is 'building Ascentage into a leading global, fully integrated hematology oncology company.' The company has made considerable progress in this regard by advancing nine global registrational trials, four of which have been cleared by both the FDA and the EMA.
The conference call also saw significant appointments to Ascentage Pharma's leadership team. Notably, Dr. Faiçal Miyara was welcomed as Chief Business Officer, bringing his wealth of experience in global business development directly relevant to the company's growth stage. Similarly, Mr. Jim Ziegler joined as Chief Commercial Officer, boasting a strong background that will aid in commercializing Ascentage Pharma's best-in-class potential therapies worldwide.
Olverembatinib, Ascentage Pharma's third-generation BCR-ABL inhibitor, has been approved for CML-CP in China since 2021 and boasts real-world long-term safety and efficacy data - an impressive milestone for a company at this stage. Plans are underway to commercialize olverembatinib in the U.S. and major pharma markets.
Another highlight was Lisaftoclax, Ascentage Pharma's selective Bcl-2 inhibitor, which has been approved as a single agent in post-BTK CLL/SLL. This achievement marks Ascentage Pharma as the second company globally to reach the market with a selective Bcl-2 inhibitor after decades of research. Furthermore, Lisaftoclax holds the distinction of being the first to be approved for use in the single-agent post-BTK CLL market.
Ascentec Pharma's late-stage pipeline is highly de-risked, boasting five additional clinical-stage assets that are conducting trials in the U.S., China, and other global regions. These include APG-2449, a triple kinase inhibitor covering FAK, ALK, ROS1; APG-115, an MDM2 inhibitor targeting both Bcl-2 and Bcl-xL; APG-1252, which targets Bcl-2 and Bcl-xL; EED inhibitor APG-5918; and the newer APG-3288 BTK degrader, which is joining phase I trials in the U.S. and China this year.
In conclusion, Ascentage Pharma has taken significant strides towards its mission of building a leading global hematology oncology company. With strengthened leadership, advanced registrational trials, and best-in-class potential therapies on the horizon, investors are likely optimistic about the company's future prospects."
